Page last updated: 2024-12-06
chlorophacinone
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
chlorophacinone: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 19402 |
| CHEMBL ID | 1874081 |
| CHEBI ID | 81796 |
| SCHEMBL ID | 18961 |
| MeSH ID | M0045800 |
Synonyms (99)
| Synonym |
|---|
| AC-19783 |
| chlorophacinone |
| 1h-indene-1,3(2h)-dione, 2-[(4-chlorophenyl)phenylacetyl]- |
| 1,3-indandione, 2-((p-chlorophenyl)phenylacetyl)- |
| 1h-indene-1,3(2h)-dione, 2-((4-chlorophenyl)phenylacetyl)- |
| redentin |
| 2(2-(4-chlorophenyl)-2-phenylacetyl)indan-1,3-dione |
| brn 2063081 |
| muriol |
| 1-(4-chlorphenyl)-1-phenyl-acetyl-indan-1,3-dion [german] |
| microzul |
| 2(2-(4-chlor-phenyl-2-phenyl)acetyl)indan-1,3-dion [german] |
| caswell no. 211c |
| lepit |
| chlorphacinon [italian] |
| 2-(alpha-p-chlorophenylacetyl)indane-1,3-dione |
| razol |
| actosin c |
| 2-((4-chlorophenyl)phenylacetyl)-1h-indene-1,3(2h)-dione |
| rozol |
| orcomolebait |
| partox |
| topitox |
| afnor |
| ((4-chlorphenyl)-1-phenyl)-acetyl-1,3-indandion [german] |
| baraage |
| caid |
| ratomet |
| drat |
| chlorfacinon [german] |
| lm 91 |
| epa pesticide chemical code 067707 |
| einecs 223-003-0 |
| 2-(alpha-p-chlorophenyl-alpha-phenylacetyl)indane-1,3-dione |
| 2-((p-chlorophenyl)phenylacetyl)-1,3-indandione |
| chloorfacinon [dutch] |
| saviac |
| 2-(2-phenyl-2-(4-chlorophenyl)acetyl)-1,3-indandione |
| chlorophacinone [bsi:iso] |
| hsdb 6432 |
| 2-(2-(4-chlorophenyl)-2-phenylacetyl)indane-1,3-dione |
| 2(2-(4-cloro-fenil-2fenil)-acetil)indan-1,3-dione [italian] |
| ratindan 3 |
| 2(2-(4-chloor-fenyl-2-fenyl)-acetyl)-indaan-1,3-dion [dutch] |
| liphadione |
| NCGC00163928-01 |
| 3691-35-8 |
| 2-[2-(4-chlorophenyl)-2-phenylacetyl]indene-1,3-dione |
| C18514 |
| chlorfacinon |
| ((4-chlorphenyl)-1-phenyl)-acetyl-1,3-indandion |
| 34y6e0063y , |
| 2(2-(4-chlor-phenyl-2-phenyl)acetyl)indan-1,3-dion |
| 2(2-(4-chloor-fenyl-2-fenyl)-acetyl)-indaan-1,3-dion |
| chlorphacinon |
| rozol prairie dog bait |
| 1-(4-chlorphenyl)-1-phenyl-acetyl-indan-1,3-dion |
| unii-34y6e0063y |
| chloorfacinon |
| 2(2-(4-cloro-fenil-2fenil)-acetil)indan-1,3-dione |
| NCGC00255247-01 |
| dtxcid0012348 |
| tox21_301565 |
| cas-3691-35-8 |
| dtxsid2032348 , |
| 2-[2-(4-chlorophenyl)-2-phenyl-ethanoyl]indene-1,3-dione |
| A823450 |
| 2-[2-(4-chlorophenyl)-1-oxo-2-phenylethyl]indene-1,3-dione |
| chlorodiphacinone |
| chlorphenacone |
| chlorophacinon |
| chlorphacinone |
| raticide-caid |
| 2-[(p-chlorophenyl)phenylacetyl]-1,3-indandione |
| AKOS015896099 |
| 2-[(4-chlorophenyl)phenylacetyl]-1h-indene-1,3(2h)-dione |
| chlorophacinone [hsdb] |
| chlorophacinone [mi] |
| ramucide |
| chlorophacinone [mart.] |
| chlorophacinone [iso] |
| 2-(2-(4-chlorophenyl)-2-phenylacetyl)indan-1, 3-dione |
| SCHEMBL18961 |
| chebi:81796 , |
| CHEMBL1874081 |
| 1,3-indandione, 2-[(p-chlorophenyl)phenylacetyl]- |
| indandione, 2-((p-chlorophenyl)phenylacetyl)- |
| ranac |
| 2(2-(4-chlor-phenyl-2-phenyl)acetyl)indan-1,3-dione |
| raviac |
| indene-1,3(2h)-dione, 2-((4-chlorophenyl)phenylacetyl)- |
| chlorophenacone |
| sakarat special |
| skaterpax |
| UDHXJZHVNHGCEC-UHFFFAOYSA-N |
| chlorophacinone, pestanal(r), analytical standard |
| 2-(2-(4-chlorophenyl)-2-phenylacetyl)-1h-indene-1,3(2h)-dione |
| BCP20502 |
| Q413488 |
Research Excerpts
Overview
Chlorophacinone is an extensively used anticoagulant rodenticide in China.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Chlorophacinone (CPN) is an extensively used anticoagulant rodenticide in China. " | ( An Yttrium-sensitized luminescence system and its application for the determination of trace chlorophacinone in serum. Cai, M; Chen, X; Jin, M, 2011) | 2.03 |
Treatment
| Excerpt | Reference | Relevance |
|---|---|---|
| "Chlorophacinone-treated and control rat samples recorded consumption of about 5 g per day." | ( Efficacy of cholecalciferol rodenticide to control wood rat, Rattus tiomanicus and its secondary poisoning impact towards barn owl, Tyto javanica javanica. Ahmad, AH; Noh, AAM; Salim, H, 2023) | 1.63 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " Massive overdose with these rodenticides justifies stomach washout when the patients are seen early, daily check-ups of coagulability and treatment with Vitamin K at a dosage adapted to the biochemical abnormalities." | ( [Prolonged hypocoagulability following the ingestion of anticoagulant raticides]. Chataigner, D; Efthymiou, ML; Elmalem, J; Garnier, R, 1989) | 0.28 |
| "Sheep were dosed with natural and synthetic anticoagulants to prolong prothrombin time (PT) in the one stage PT test." | ( Stability of prothrombin times in sheep dosed with natural and synthetic anticoagulants. Egyed, MN; Shlosberg, A, 1986) | 0.27 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (2)
| Class | Description |
|---|---|
| diarylmethane | Any compound containing two aryl groups connected by a single C atom. |
| beta-triketone | A triketone in which the each ketone functionality is located beta- to the other two. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Protein Targets (30)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| hypoxia-inducible factor 1 alpha subunit | Homo sapiens (human) | Potency | 54.9410 | 3.1890 | 29.8841 | 59.4836 | AID1224846 |
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 6.4272 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521; AID1159523 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 47.6695 | 0.0007 | 14.5928 | 83.7951 | AID1259369; AID1259392 |
| AR protein | Homo sapiens (human) | Potency | 21.6509 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID1259247; AID743035; AID743042; AID743054; AID743063 |
| estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 7.6959 | 0.0006 | 57.9133 | 22,387.1992 | AID1259378 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 68.5896 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224839 |
| progesterone receptor | Homo sapiens (human) | Potency | 12.0935 | 0.0004 | 17.9460 | 75.1148 | AID1346784; AID1346795 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 18.4205 | 0.0002 | 14.3764 | 60.0339 | AID720691; AID720692 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 36.9575 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159555 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 4.0047 | 0.0008 | 17.5051 | 59.3239 | AID1159527; AID1159531 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 8.8223 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403 |
| farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 17.3739 | 0.3758 | 27.4851 | 61.6524 | AID743217 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 31.9998 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982; AID720659 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 31.9545 | 0.0002 | 29.3054 | 16,493.5996 | AID1259244; AID1259248; AID743069; AID743075; AID743078; AID743079; AID743080; AID743091 |
| peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 43.6412 | 0.0010 | 24.5048 | 61.6448 | AID743215 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 27.5076 | 0.0010 | 19.4141 | 70.9645 | AID588537; AID743191 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 54.4827 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
| activating transcription factor 6 | Homo sapiens (human) | Potency | 24.5412 | 0.1434 | 27.6121 | 59.8106 | AID1159516 |
| thyrotropin-releasing hormone receptor | Homo sapiens (human) | Potency | 2.9186 | 0.1549 | 17.8702 | 43.6557 | AID1346877; AID1346891 |
| nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | Homo sapiens (human) | Potency | 48.9662 | 19.7391 | 45.9784 | 64.9432 | AID1159509 |
| v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 34.6654 | 0.0578 | 21.1097 | 61.2679 | AID1159526 |
| Histone H2A.x | Cricetulus griseus (Chinese hamster) | Potency | 113.0040 | 0.0391 | 47.5451 | 146.8240 | AID1224845; AID1224896 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 14.7881 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743067 |
| heat shock protein beta-1 | Homo sapiens (human) | Potency | 43.9307 | 0.0420 | 27.3789 | 61.6448 | AID743210; AID743228 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 42.0454 | 0.0006 | 27.2152 | 1,122.0200 | AID651741; AID743202; AID743219 |
| Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 27.3060 | 0.0015 | 57.7890 | 15,848.9004 | AID1259244 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 62.8779 | 0.0023 | 19.5956 | 74.0614 | AID651631; AID720552 |
| Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 27.3060 | 0.0015 | 51.7393 | 15,848.9004 | AID1259244 |
| ATPase family AAA domain-containing protein 5 | Homo sapiens (human) | Potency | 2.7306 | 0.0119 | 17.9420 | 71.5630 | AID651632 |
| Ataxin-2 | Homo sapiens (human) | Potency | 2.7306 | 0.0119 | 12.2221 | 68.7989 | AID651632 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (141)
Molecular Functions (40)
Ceullar Components (27)
Research
Studies (48)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 14 (29.17) | 18.7374 |
| 1990's | 6 (12.50) | 18.2507 |
| 2000's | 11 (22.92) | 29.6817 |
| 2010's | 12 (25.00) | 24.3611 |
| 2020's | 5 (10.42) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 42.60
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (42.60) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (1.85%) | 5.53% |
| Reviews | 1 (1.85%) | 6.00% |
| Case Studies | 9 (16.67%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 43 (79.63%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||